Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR3006-1
- Development stage
- Unknown
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BR3006-1 is an investigational drug developed by Boryung for the treatment of diabetes mellitus, including type 2 diabetes. It is currently being studied in early-phase clinical trials to evaluate its pharmacokinetics, safety, and potential drug-drug interactions in healthy volunteers. The specific mechanism of action and molecular target for BR3006-1 have not been disclosed publicly. Clinical studies involve both single oral administration and co-administration with related compounds (BR3006A, BR3006B, and BR3006C). As of now, there are no approved indications or known adverse events reported for this compound.
- Other names
- BR3006-1BR-3006-1BR 3006-1
Beyond the preview
Go deeper on BR3006-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR3006-1.